EntryPoint Capital’s Bioventus BVS Stock Holding History

EntryPoint Capital’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$167K	Sell	17,732 -5,696	-24%	-$54.4K	0.04%	715
2026 Q1	$214K	Hold	23,428	–	–	0.06%	617
2025 Q4	$174K	Buy	+23,428	New	+$168K	0.07%	571
2025 Q3	–	Sell	-12,548	Closed	-$83.1K	–	682
2025 Q2	$83.1K	Sell	12,548 -15,823	-56%	-$112K	0.04%	573
2025 Q1	$260K	Buy	28,371 +2,048	+8%	+$20.5K	0.12%	408
2024 Q4	$276K	Sell	26,323 -12,979	-33%	-$154K	0.12%	425
2024 Q3	$470K	Sell	39,302 -28,922	-42%	-$250K	0.27%	65
2024 Q2	$392K	Buy	+68,224	New	+$374K	0.18%	86
2024 Q1	–	Sell	-9,335	Closed	-$49.2K	–	1448
2023 Q4	$49.2K	Buy	+9,335	New	+$36.9K	0.05%	725

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JIC

Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EntryPoint Capital's BVS Position: Q2 2026 in Review

EntryPoint Capital reduced its Bioventus (BVS) stake by 24% in Q2 2026, selling an estimated $54.4K and leaving 17,732 shares worth $167K. The position accounts for 0.04% of the portfolio, ranked #715.

EntryPoint Capital first reported a position in BVS in Q4 2023 and has held it in 9 quarters since. The position peaked at $470K in Q3 2024. 157 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

EntryPoint Capital held 17,732 shares of Bioventus worth $167K as of Q2 2026.
EntryPoint Capital sold 5,696 Bioventus shares in Q2 2026, an estimated $54.4K.
Bioventus made up 0.04% of EntryPoint Capital's portfolio in Q2 2026, its #715 holding.
EntryPoint Capital first reported a position in Bioventus in Q4 2023 and has held it in 9 quarters since.
EntryPoint Capital's Bioventus position peaked at $470K in Q3 2024.
157 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.